KR101849680B1 - 아밀로이드 결합제 - Google Patents

아밀로이드 결합제 Download PDF

Info

Publication number
KR101849680B1
KR101849680B1 KR1020127017823A KR20127017823A KR101849680B1 KR 101849680 B1 KR101849680 B1 KR 101849680B1 KR 1020127017823 A KR1020127017823 A KR 1020127017823A KR 20127017823 A KR20127017823 A KR 20127017823A KR 101849680 B1 KR101849680 B1 KR 101849680B1
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
compound
alkyl
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127017823A
Other languages
English (en)
Korean (ko)
Other versions
KR20120104306A (ko
Inventor
제리 양
엠마뉴엘 에이. 테오도라키스
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20120104306A publication Critical patent/KR20120104306A/ko
Application granted granted Critical
Publication of KR101849680B1 publication Critical patent/KR101849680B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020127017823A 2009-12-10 2010-12-10 아밀로이드 결합제 Active KR101849680B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28547009P 2009-12-10 2009-12-10
US61/285,470 2009-12-10
PCT/US2010/059952 WO2011072257A2 (en) 2009-12-10 2010-12-10 Amyloid binding agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187010217A Division KR20180041767A (ko) 2009-12-10 2010-12-10 아밀로이드 결합제

Publications (2)

Publication Number Publication Date
KR20120104306A KR20120104306A (ko) 2012-09-20
KR101849680B1 true KR101849680B1 (ko) 2018-04-17

Family

ID=44146211

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020127017823A Active KR101849680B1 (ko) 2009-12-10 2010-12-10 아밀로이드 결합제
KR1020187010217A Ceased KR20180041767A (ko) 2009-12-10 2010-12-10 아밀로이드 결합제
KR1020197027350A Active KR102079160B1 (ko) 2009-12-10 2010-12-10 아밀로이드 결합제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187010217A Ceased KR20180041767A (ko) 2009-12-10 2010-12-10 아밀로이드 결합제
KR1020197027350A Active KR102079160B1 (ko) 2009-12-10 2010-12-10 아밀로이드 결합제

Country Status (25)

Country Link
US (3) US8940918B2 (https=)
EP (1) EP2509940B1 (https=)
JP (1) JP5591946B2 (https=)
KR (3) KR101849680B1 (https=)
CN (2) CN105669597B (https=)
AU (1) AU2010327918B2 (https=)
BR (1) BR112012013810B1 (https=)
CA (1) CA2783466C (https=)
CY (1) CY1116487T1 (https=)
DK (1) DK2509940T3 (https=)
ES (1) ES2546063T3 (https=)
HR (1) HRP20150854T1 (https=)
HU (1) HUE027199T2 (https=)
IN (1) IN2012DN05186A (https=)
ME (1) ME02194B (https=)
MX (1) MX347591B (https=)
NZ (1) NZ600459A (https=)
PL (1) PL2509940T3 (https=)
PT (1) PT2509940E (https=)
RS (1) RS54158B1 (https=)
RU (1) RU2517174C2 (https=)
SG (1) SG181561A1 (https=)
SI (1) SI2509940T1 (https=)
SM (1) SMT201500216B (https=)
WO (1) WO2011072257A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013180815A1 (en) * 2012-05-30 2013-12-05 University Of Tennessee Research Foundation Compounds for amide-forming reactions
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
AR098232A1 (es) * 2013-10-31 2016-05-18 Cognoptix Inc Métodos de preparación de una formulación oftálmica y usos de la misma
EP3068283A1 (en) * 2013-11-12 2016-09-21 Cognoptix, Inc. Method for measuring fluorescence in ocular tissue
AU2015231239B2 (en) 2014-03-19 2018-11-29 Amydis, Inc. Amyloid targeting agents and methods of using the same
WO2016040891A2 (en) * 2014-09-12 2016-03-17 Amydis Diagnostics In vitro compositions comprising human sample and amyloid targeting agent
US11286233B2 (en) 2017-05-09 2022-03-29 Ambient Photonics, Inc. Stilbene derivatives for the treatment of CNS and other disorders
MA52796A (fr) * 2018-05-31 2021-04-14 Amydis Inc Compositions et procédés de détection d'une lésion cérébrale traumatique
AU2019372432B2 (en) * 2018-11-02 2025-05-29 Amydis, Inc. Phosphate compounds for detecting neurological disorders
KR102240400B1 (ko) 2020-11-19 2021-04-15 한국원자력연구원 베타-아밀로이드 검출용 수용성 화합물
IL305647A (en) * 2021-03-12 2023-11-01 Amydis Inc Methods for the detection of systemic amyloidosis by binding to misfolded protein or aggregates
WO2022266210A1 (en) * 2021-06-16 2022-12-22 The Regents Of The University Of California Amyloid targeting agents and methods of using the same
CN115322165A (zh) * 2022-09-30 2022-11-11 镇江百单医疗生物科技有限公司 近红外荧光探针成像肝纤维化中亚铁离子的动态波动

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073697A1 (en) * 2004-01-20 2005-08-11 The Curators Of The University Of Missouri Local flow and shear stress sensor based on molecular rotors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583614A (en) * 1950-05-13 1952-01-29 Eastman Kodak Co Acylated methine dye compounds
US2798090A (en) * 1953-03-02 1957-07-02 Eastman Kodak Co Process for preparing benzalaniline-3-sulfonic acid compounds
US3074971A (en) * 1959-01-23 1963-01-22 Gen Aniline & Film Corp alpha-cyanocinnamic acid esters
US3149146A (en) * 1960-03-09 1964-09-15 Gen Aniline & Film Corp Alpha-cyano-2-alkenoxy-1-naphthaleneacrylic acid esters
FR1321641A (fr) * 1962-03-08 1963-03-22 Gen Aniline & Film Corp Nouvelles compositions absorbantes de rayons ultraviolets
BE794010A (fr) * 1972-01-13 1973-05-02 Du Pont Colorants cationiques de couleur jaune-vert
DE2714653C3 (de) 1977-04-01 1980-10-30 Bayer Ag, 5090 Leverkusen Kationische Styrylfarbstoffe und Verfahren zum Färben mit diesen Farbstoffen
DE2942185A1 (de) * 1979-10-18 1981-04-30 Basf Ag, 6700 Ludwigshafen Basische farbstoffe
JPS5815912A (ja) * 1981-07-22 1983-01-29 Ss Pharmaceut Co Ltd 消炎鎮痛剤
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS63163826A (ja) * 1986-12-26 1988-07-07 Idemitsu Kosan Co Ltd 有機非線型光学材料
DE3905916A1 (de) * 1989-02-25 1990-08-30 Basf Ag Verwendung von derivaten des n-phenyl-3,4,5,6-tetrahydrophthalimids zur desikkation und abszission von pflanzenorganen
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE4430691A1 (de) * 1994-08-30 1996-03-07 Bayer Ag Elektrolumineszierende Anordnungen und deren Verwendung
US7563820B2 (en) * 2002-01-18 2009-07-21 The Hospital For Sick Children Compounds for modulating cell proliferation
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
JP2006519874A (ja) 2003-03-05 2006-08-31 セルジーン・コーポレーション ジフェニルエチレン化合物およびその使用
EP1727822A4 (en) * 2004-03-26 2007-05-09 Hsc Res Dev Lp NEW COMPOUNDS FOR MODULATING CELL PROLIFERATION
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
WO2007011834A2 (en) 2005-07-15 2007-01-25 The Regents Of The University Of California Compounds and method for the diagnosis and treatment of amyloid associated diseases
PL2049253T3 (pl) 2006-07-31 2020-03-31 Basf Se Zintegrowany sposób obejmujący uwodornianie za pomocą katalizatorów rutenowych i ich regenerację
FR2905009A1 (fr) * 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
CN101209976B (zh) * 2006-12-29 2012-01-11 中国人民解放军军事医学科学院毒物药物研究所 取代的酒石酸衍生物及其用于制备β-分泌酶抑制剂的用途
EP2217930B1 (en) * 2007-10-24 2013-03-06 Tallinn University Of Technology Maldi ms-based high-throughput screening method for substances inhibiting aggregation of alzheimer's amyloid beta peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073697A1 (en) * 2004-01-20 2005-08-11 The Curators Of The University Of Missouri Local flow and shear stress sensor based on molecular rotors

Also Published As

Publication number Publication date
CA2783466C (en) 2019-09-24
HK1177930A1 (en) 2013-08-30
RU2517174C2 (ru) 2014-05-27
EP2509940A4 (en) 2013-04-17
CY1116487T1 (el) 2017-03-15
SMT201500216B (it) 2015-10-30
PT2509940E (pt) 2015-09-24
CN103201258B (zh) 2016-01-27
RU2012128798A (ru) 2014-01-20
US8940918B2 (en) 2015-01-27
MX2012006552A (es) 2012-08-23
CN103201258A (zh) 2013-07-10
DK2509940T3 (en) 2015-07-20
ME02194B (me) 2016-02-20
US20170315137A1 (en) 2017-11-02
SG181561A1 (en) 2012-07-30
PL2509940T3 (pl) 2015-11-30
BR112012013810A2 (pt) 2020-08-25
WO2011072257A2 (en) 2011-06-16
US9551722B2 (en) 2017-01-24
NZ600459A (en) 2014-01-31
JP2013513619A (ja) 2013-04-22
EP2509940A2 (en) 2012-10-17
US20120302603A1 (en) 2012-11-29
CA2783466A1 (en) 2011-06-16
KR20190109594A (ko) 2019-09-25
AU2010327918B2 (en) 2014-01-16
JP5591946B2 (ja) 2014-09-17
WO2011072257A3 (en) 2011-10-20
ES2546063T3 (es) 2015-09-18
HUE027199T2 (en) 2016-08-29
AU2010327918A1 (en) 2012-06-21
KR20120104306A (ko) 2012-09-20
HRP20150854T1 (hr) 2015-09-25
BR112012013810B1 (pt) 2022-01-11
US20150177262A1 (en) 2015-06-25
HK1225729A1 (zh) 2017-09-15
IN2012DN05186A (https=) 2015-10-23
KR102079160B1 (ko) 2020-02-19
EP2509940B1 (en) 2015-06-10
CN105669597B (zh) 2019-05-07
MX347591B (es) 2017-05-03
SI2509940T1 (sl) 2015-09-30
KR20180041767A (ko) 2018-04-24
RS54158B1 (sr) 2015-12-31
CN105669597A (zh) 2016-06-15

Similar Documents

Publication Publication Date Title
KR101849680B1 (ko) 아밀로이드 결합제
JP7664201B2 (ja) アミロイド標的剤及びその使用方法
EP3298015B1 (en) Pyrazolopyrimidine derivatives
Sozmen et al. Designing BODIPY-based probes for fluorescence imaging of β-amyloid plaques
US20240299589A1 (en) Diagnosing and treating cancer
JP2008519822A (ja) アミロイド関連疾患を治療するための方法およびフッ素化組成物
JP2025060830A (ja) ロイコトリエン合成阻害剤
WO2024015730A2 (en) Amphiphilic compounds for attenuating neurotoxicity of amyloid-beta oligomers and diagnostic methods
JP7652791B2 (ja) α－シヌクレインの凝集に関連する疾患の診断、治療および予防のための新規な化合物
KR101282885B1 (ko) 스티릴피리다진온 유도체를 이용한 아밀로이드 단백질 응집물의 검출 방법
HK1225729B (zh) 淀粉状蛋白结合剂
HK1177930B (en) Amyloid binding agents
CN103338767A (zh) 治疗炎症性疾病的组合物和方法
WO2022266210A1 (en) Amyloid targeting agents and methods of using the same
KR20250131205A (ko) 베타-아밀로이드 검출용 인데인 기반 화합물
CN121873043A (zh) 靶向降解Sigma-1受体的PROTAC化合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120709

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
AMND Amendment
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151208

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170119

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171107

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170119

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20171107

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170719

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20151208

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20130723

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20130118

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20180111

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20171207

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20171107

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20170719

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20151208

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20130723

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20130118

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180411

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180411

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180412

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20210326

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20210326

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20220325

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20220325

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230328

Start annual number: 6

End annual number: 6